Phio Pharmaceuticals Corp. (NASDAQ:PHIO) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on August 14, 2026.
At publication ·
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) · proxy filed
At a glance
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on August 14, 2026.
The Healthcare company's proxy statement provides information for shareholders ahead of the annual meeting, including board nominations, executive compensation, and proposals for shareholder vote.
Phio Pharmaceuticals Corp.'s stock currently trades at $1.09 with a market capitalization of $12.4M.
SEC filings provide mandatory disclosures that give investors access to the same material information available to institutional investors. Reviewing Phio Pharmaceuticals Corp.'s filings alongside price action and analyst commentary provides a more complete picture of the company's current situation.
All SEC filings for Phio Pharmaceuticals Corp. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View PHIO Stock Page
Browse all filings on our PHIO SEC filings page.
Public companies like Phio Pharmaceuticals Corp. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Current market data
NASDAQ · PHIO
$1.03
Down: -$0.02 · -1.94%
Live quote updated
Keep reading
earnings ·
earnings ·
sec_filing ·
earnings ·
